Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

Romberg test was not performed before the intervention due to trunk instability; after treatment participants presented minimal balance changes ... peripheral nerves are relatively scarce, given that ...

ABOUT CARVYKTI® (CILTACABTAGENE AUTOLEUCEL; CILTA-CEL) ...

Annexon's lead investigational therapy, tanruprubart, is a first-of-its kind selective, targeted and rapid-acting agent designed to reduce inflammation and nerve damage by stopping C1q activity in the ...

at the 2025 Peripheral Nerve Society (PNS) Annual Meeting being held May 17-20, 2025 in Edinburgh, UK. GBS is a neuromuscular emergency and rare autoimmune disease that affects at least 150,000 ...

Discover the major causes of partial paralysis from stroke and trauma to inflammatory conditions and tumors, plus warning ...

In GBS, tanruprubart is designed to seek out C1q and prevent its binding to targets on peripheral nerves. Tanruprubart is administered intravenously and has been observed to act almost immediately ...

In GBS, tanruprubart is designed to seek out C1q and prevent its binding to targets on peripheral nerves. Tanruprubart is administered intravenously and has been observed to act almost immediately ...

For many veterans, dealing with injuries or mental health conditions after service is hard enough. Add in the complexity of the VA's disability rating system, and it can feel like ...

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...